nach oben

Erschienen in:

01.05.2014 | Oncology

Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer

verfasst von: Connie Yip, Vicky Goh, Andrew Davies, James Gossage, Rosalind Mitchell-Hay, Orla Hynes, Nick Maisey, Paul Ross, Andrew Gaya, David B. Landau, Gary J. Cook, Nyree Griffin, Robert Mason

Erschienen in: European Radiology | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Sarcopenia and changes in body composition following neoadjuvant chemotherapy (NAC) may affect clinical outcome. We assessed the associations between CT body composition changes following NAC and outcomes in oesophageal cancer.

Methods

A total of 35 patients who received NAC followed by oesophagectomy, and underwent CT assessment pre- and post-NAC were included. Fat mass (FM), fat-free mass (FFM), subcutaneous fat to muscle ratio (FMR) and visceral to subcutaneous adipose tissue ratio (VA/SA) were derived from CT. Changes in FM, FFM, FMR, VA/SA and sarcopenia were correlated to chemotherapy dose reductions, postoperative complications, length of hospital stay (LOS), circumferential resection margin (CRM), pathological chemotherapy response, disease-free survival (DFS) and overall survival (OS).

Results

Nine (26 %) patients were sarcopenic before NAC and this increased to 15 (43 %) after NAC. Average weight loss was 3.7 % ± 6.4 (SD) in comparison to FM index (−1.2 ± 4.2), FFM index (−4.6 ± 6.8), FMR (−1.2 ± 24.3) and VA/SA (−62.3 ± 12.7). Changes in FM index (p = 0.022), FMR (p = 0.028), VA/SA (p = 0.024) and weight (p = 0.007) were significant univariable factors for CRM status. There was no significant association between changes in body composition and survival.

Conclusions

Loss of FM, differential loss of VA/SA and skeletal muscle were associated with risk of CRM positivity.

Key Points

• Changes in CT body composition occur after neoadjuvant chemotherapy in oesophageal cancer.

• Sarcopenia was more prevalent after neoadjuvant chemotherapy.

• Fat mass, fat-free mass and weight decreased after neoadjuvant chemotherapy.

• Changes in body composition were associated with CRM positivity.

• Changes in body composition did not affect perioperative complications and survival.

Nur mit Berechtigung zugänglich

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRef

Cancer Research UK (2012) Oesophageal cancer survival statistics, Cancer Research UK, London. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/oesophagus/survival/. Accessed 2 Sept 2013

Berger B, Belka C (2009) Evidence-based radiation oncology: oesophagus. Radiother Oncol 92:276–290PubMedCrossRef

Baumgartner RN, Koehler KM, Gallagher D et al (1998) Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 147:755–763PubMedCrossRef

Janssen I, Heymsfield SB, Ross R (2002) Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 50:889–896PubMedCrossRef

Cosqueric G, Sebag A, Ducolombier C, Thomas C, Piette F, Weill-Engerer S (2006) Sarcopenia is predictive of nosocomial infection in care of the elderly. Br J Nutr 96:895–901PubMedCrossRef

Pichard C, Kyle UG, Morabia A, Perrier A, Vermeulen B, Unger P (2004) Nutritional assessment: lean body mass depletion at hospital admission is associated with an increased length of stay. Am J Clin Nutr 79:613–618PubMed

McClave SA, Snider HL, Spain DA (1999) Preoperative issues in clinical nutrition. Chest 115:64S–70SPubMedCrossRef

Prado CM, Baracos VE, McCargar LJ et al (2007) Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 13:3264–3268PubMedCrossRef

10.

Prado CM, Baracos VE, McCargar LJ et al (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15:2920–2926PubMedCrossRef

11.

Prado CM, Lima IS, Baracos VE et al (2011) An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol 67:93–101PubMedCrossRef

12.

Balentine CJ, Enriquez J, Fisher W et al (2010) Intra-abdominal fat predicts survival in pancreatic cancer. J Gastrointest Surg 14:1832–1837PubMedCrossRef

13.

Prado CM, Lieffers JR, McCargar LJ et al (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9:629–635PubMedCrossRef

14.

Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC (2009) Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 15:6973–6979PubMedCrossRef

15.

Awad S, Tan BH, Cui H et al (2012) Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin Nutr 31:74–77PubMedCrossRef

16.

Bower MR, Martin RC 2nd (2009) Nutritional management during neoadjuvant therapy for esophageal cancer. J Surg Oncol 100:82–87PubMedCrossRef

17.

Mandard AM, Dalibard F, Mandard JC et al (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73:2680–2686PubMedCrossRef

18.

Mapstone NP (2007) Dataset for the histopathological reporting of oesophageal carcinoma, 2nd edn. Royal College of Pathologists, London

19.

Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R (1998) Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol 85:115–122PubMed

20.

Kvist H, Sjostrom L, Tylen U (1986) Adipose tissue volume determinations in women by computed tomography: technical considerations. Int J Obes 10:53–67PubMed

21.

Vehmas T, Kairemo KJ, Taavitsainen MJ (1996) Measuring visceral adipose tissue content from contrast enhanced computed tomography. Int J Obes Relat Metab Disord 20:570–573PubMed

22.

Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE (2008) A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33:997–1006PubMedCrossRef

23.

Ibrahim MM (2010) Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev 11:11–18PubMedCrossRef

24.

Kuk JL, Katzmarzyk PT, Nichaman MZ, Church TS, Blair SN, Ross R (2006) Visceral fat is an independent predictor of all-cause mortality in men. Obesity 14:336–341PubMedCrossRef

25.

Moon HG, Ju YT, Jeong CY et al (2008) Visceral obesity may affect oncologic outcome in patients with colorectal cancer. Ann Surg Oncol 15:1918–1922PubMedCrossRef

26.

Clark W, Siegel EM, Chen YA et al (2013) Quantitative measures of visceral adiposity and body mass index in predicting rectal cancer outcomes after neoadjuvant chemoradiation. J Am Coll Surg 216:1070–1081PubMedCrossRef

27.

Sheetz KH, Zhao L, Holcombe SA et al (2013) Decreased core muscle size is associated with worse patient survival following esophagectomy for cancer. Dis Esophagus 26:716–722PubMed

Titel: Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer
verfasst von: Connie Yip
Vicky Goh
Andrew Davies
James Gossage
Rosalind Mitchell-Hay
Orla Hynes
Nick Maisey
Paul Ross
Andrew Gaya
David B. Landau
Gary J. Cook
Nyree Griffin
Robert Mason
Publikationsdatum: 01.05.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: European Radiology / Ausgabe 5/2014
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-014-3110-4

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer